{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:10:20Z","timestamp":1779275420347,"version":"3.51.4"},"reference-count":72,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Medication nonadherence is a prevalent issue in the oncology population and can be costly on the healthcare system while leading to worsened outcomes, including increased mortality. One intervention that has been shown to help promote medication adherence to oral therapies for chronic conditions is blister-packaging. However, no literature is available assessing the potential impact of blister-packaging in oncology. Therefore, we aimed to quantify the impact of blister-packaging oral oncolytics on medication adherence and healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An economic model was designed to assess the potential impact of blister-packaging oral oncolytics for chronic lymphocytic leukemia (CLL) patients in the U.S. The model took the perspective of the U.S. healthcare system and assessed newly diagnosed CLL cases initiating therapy, utilizing a one-year time horizon. The intervention of interest was blister-packaging oral therapies in the treatment of CLL, while the model evaluated the impact of this intervention on healthcare costs through improved patient adherence based on peer-reviewed literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis consisted of 20,700 newly diagnosed patients with CLL initiating therapy. Initiating blister-packed oral therapies saw adherence increase by 1004 patients from 12,979 patients (62.7%) to 13,983 patients (67.5%). While an increase in pharmacy costs by $61,589,670 (+$247.95 per-patient per-month (PPPM)) was seen for the population, medical costs decreased by $82,285,847 (-$331.26 PPPM). Overall, this led to a net reduction in total healthcare costs of $20,696,177 (-$83.32 PPPM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Blister-packaging oral oncology drugs in CLL has the potential to reduce total healthcare expenditures by increasing medication adherence. Future studies are needed to evaluate the direct effects of blister-packaging oral oncolytics on clinical, healthcare resource utilization, and financial outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241306704","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:01:46Z","timestamp":1739959306000},"page":"648-658","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing medication adherence with blister-packed oral oncolytics: A case example in chronic lymphocytic leukemia"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-9893","authenticated-orcid":false,"given":"Eric P.","family":"Borrelli","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research, Becton, Dickinson and Company, San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Barnes","sequence":"additional","affiliation":[{"name":"Medical Affairs, Becton, Dickinson and Company"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Nelkin","sequence":"additional","affiliation":[{"name":"Medical Affairs, Becton, Dickinson and Company, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Saad","sequence":"additional","affiliation":[{"name":"Medical Affairs, Becton, Dickinson and Company"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doina","family":"Dumitru","sequence":"additional","affiliation":[{"name":"Medical Affairs, Becton, Dickinson and Company, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia D.","family":"Lucaci","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Becton, Dickinson and Company"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis","volume":"11","author":"Foley L","unstructured":"Foley L, Larkin J, Lombard-Vance R, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. BMJ Open 2021 Sep 2; 11: e044987.","journal-title":"BMJ Open"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2022.2144923"},{"key":"e_1_3_2_4_2","article-title":"Economic impact of medication non-adherence by disease groups: a systematic review","volume":"8","author":"Cutler RL","unstructured":"Cutler RL, Fernandez-Llimos F, Frommer M, et al. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 2018 Jan 21; 8: e016982.","journal-title":"BMJ Open"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0405"},{"key":"e_1_3_2_6_2","first-page":"25","article-title":"Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review","volume":"23","author":"Eliassen FM","unstructured":"Eliassen FM, Bl\u00e5fjelldal V, Helland T, et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer 2023 Jul 4; 23: 25.","journal-title":"BMC Cancer"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22019"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1132-4"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.5983"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211000208"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0001"},{"key":"e_1_3_2_12_2","first-page":"1609","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek D","unstructured":"Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 2016 Aug 24; 10: 1609\u20131621.","journal-title":"Patient Prefer Adherence"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001183"},{"key":"e_1_3_2_14_2","first-page":"227","article-title":"Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer","volume":"22","author":"Seal BS","unstructured":"Seal BS, Anderson S, Shermock KM. Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer. J Manag Care Spec Pharm 2016 Mar; 22: 227\u2013235.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_15_2","article-title":"Challenges to oral chemotherapy adherence","volume":"44","author":"Thomas SA","year":"2019","unstructured":"Thomas SA, John T, Criner E, et al. Challenges to oral chemotherapy adherence. US Pharm 2019; 44: HS-9\u2013HS-12.","journal-title":"US Pharm"},{"key":"e_1_3_2_16_2","first-page":"831","article-title":"Predictors of adherence to oral anticancer medications: an analysis of 2010\u20132018 US nationwide claims","volume":"28","author":"Vyas A","unstructured":"Vyas A, Descoteaux A, Kogut S, et al. Predictors of adherence to oral anticancer medications: an analysis of 2010\u20132018 US nationwide claims. J Manag Care Spec Pharm 2022 Aug; 28: 831\u2013844.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.10.016"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.978939"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02297"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.04.020"},{"key":"e_1_3_2_21_2","unstructured":"Leukemia & Lymphoma Society. Updated data on blood cancers: facts 2022\u20132023. Leukemia & Lymphoma Society https:\/\/www.lls.org\/sites\/default\/files\/2023-08\/PS80_Facts_2022_2023.pdf (2023 Aug accessed 12 March 2024 accessed 22 March 2024)."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_2_23_2","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer stat facts: leukemia \u2013 chronic lymphocytic leukemia (CLL). National Cancer Institute: Surveillance Epidemiology and End Results Program https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html (2024 accessed 12 March 2024)."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153859"},{"key":"e_1_3_2_25_2","unstructured":"Wierda WG Brown J Abramson JS et al. NCCN Clinical Practice Guidelines in Oncology: Chronic lymphocytic leukemia\/small lymphocytic lymphoma version 2.2024. National Comprehensive Cancer Network https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf (2024 Mar 11 accessed 12 March 2024)."},{"key":"e_1_3_2_26_2","first-page":"186","article-title":"Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"26","author":"Dashputre AA","unstructured":"Dashputre AA, Gatwood KS, Gatwood J. Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Manag Care Spec Pharm 2020 Feb; 26: 186\u2013196.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S417180"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2255326"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000700"},{"key":"e_1_3_2_30_2","first-page":"326","article-title":"Association between adherence with oral anticancer medications and short-term health care resource utilization: a 2010\u20132018 claims-based analysis","volume":"30","author":"Vyas A","unstructured":"Vyas A, Parikh MA, Campbell PJ, et al. Association between adherence with oral anticancer medications and short-term health care resource utilization: a 2010\u20132018 claims-based analysis. J Manag Care Spec Pharm. 2024 Apr; 30: 326\u2013335.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129930"},{"key":"e_1_3_2_32_2","article-title":"Comparative efficacy of first-line treatments of chronic lymphocytic leukemia: network meta-analyses of survival curves","volume":"21","author":"Alrawashdh N","unstructured":"Alrawashdh N, Persky DO, McBride A, et al. Comparative efficacy of first-line treatments of chronic lymphocytic leukemia: network meta-analyses of survival curves. Clin Lymphoma Myeloma Leuk 2021 Nov; 21: e820\u2013e831.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_2_33_2","unstructured":"Kumar SK Callander NS Adekola K et al. NCCN clinical practice guidelines in oncology: multiple myeloma version 3.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf (2024 Mar 8 accessed 15 March 2024)."},{"key":"e_1_3_2_34_2","unstructured":"US Inflation Calculator. Health care inflation in the United States (1948\u20132024). US Inflation Calculator https:\/\/www.usinflationcalculator.com\/inflation\/health-care-inflation-in-the-united-states\/ (accessed 12 March 2024)."},{"key":"e_1_3_2_35_2","unstructured":"Gradishar WJ Moran MS Abraham J et al. NCCN clinical practice guidelines in oncology: breast cancer version 2.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (2024 Mar 11 accessed 15 March 2024)."},{"key":"e_1_3_2_36_2","unstructured":"Shah NP Bhatia R Altman JK et al. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia version 2.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf (2023 Dec 5 accessed 15 March 2024)."},{"key":"e_1_3_2_37_2","unstructured":"Benson AB Venook AP Adam M et al. NCCN clinical practice guidelines in oncology: colon cancer version 1.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf (2024 Jan 29 accessed 15 March 2024)."},{"key":"e_1_3_2_38_2","unstructured":"Riely GJ Wood DE Ettinger DS et al. NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 3.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf (2024 Mar 12 accessed 15 March 2024)."},{"key":"e_1_3_2_39_2","unstructured":"Armstrong DK Alvarez RD Backes FJ et al. NCCN clinical practice guidelines in oncology: ovarian cancer version 1.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf (2024 Jan 17 accessed 15 March 2024)."},{"key":"e_1_3_2_40_2","unstructured":"Schaeffer EM Srinivas S Adra N et al. NCCN clinical practice guidelines in oncology: prostate cancer version 3.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (2024 Mar 8 accessed 15 March 2024)."},{"key":"e_1_3_2_41_2","unstructured":"Motzer RJ Jonasch E Agarwal N et al. NCCN clinical practice guidelines in oncology: kidney cancer version 3.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf (2024 Mar 11 accessed 15 March 2024)."},{"key":"e_1_3_2_42_2","unstructured":"BC Cancer. BC Cancer pharmacy practice standards for hazardous drugs: improving patient safety and compliance Module 3. BC Cancer http:\/\/www.bccancer.bc.ca\/pharmacy-site\/Documents\/Safe%20Handling\/4%20%20Module%203_Improving%20Patient%20Safety%20and%20Compliance.pdf (2024 Apr accessed 6 June 2024)."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29080456"},{"key":"e_1_3_2_44_2","unstructured":"Dentzer S Hubbard T. Value-Based contracting for oncology drugs: A NEHI White Paper. NEHI Network for Excellence in Health Innovation https:\/\/www.phrma.org\/-\/media\/Project\/PhRMA\/PhRMA-Org\/PhRMA-Org\/PDF\/M-O\/NEHI_VBCOncology_Final.pdf (2017 accessed 3 April 2024)."},{"key":"e_1_3_2_45_2","unstructured":"Shvets E McCarthy KF Neal JC et al. Survey finds 58% of payers use outcomes-based contracts. Avalere https:\/\/avalere.com\/insights\/58-of-payers-use-outcomes-based-contracts (2023 Apr 5 accessed 3 April 2024)."},{"key":"e_1_3_2_46_2","first-page":"386","article-title":"A primer on quality measurement and reporting in pharmacy benefit plans","volume":"30","author":"Kogut SJ","unstructured":"Kogut SJ. A primer on quality measurement and reporting in pharmacy benefit plans. J Manag Care Spec Pharm 2024 Apr; 30: 386\u2013396.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_47_2","unstructured":"National Community Oncology Dispensing Association. NCODA accreditation program. National Community Oncology Dispensing Association https:\/\/www.ncoda.org\/accreditation\/ (2021 accessed 3 April 2024)."},{"key":"e_1_3_2_48_2","unstructured":"URAC. Specialty pharmacy accreditation. URAC https:\/\/www.urac.org\/accreditation-cert\/specialty-pharmacy\/ (2024 accessed 3 April 2024)."},{"key":"e_1_3_2_49_2","article-title":"Association between medication adherence and non-drug healthcare utilisation and costs: a retrospective longitudinal cohort study among US women age 65 and older","volume":"11","author":"Ma S","unstructured":"Ma S, Shepard DS, Ritter GA, et al. Association between medication adherence and non-drug healthcare utilisation and costs: a retrospective longitudinal cohort study among US women age 65 and older. BMJ Open 2021 Dec 7; 11: e052146.. PMID: 34876428.","journal-title":"BMJ Open"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903396469"},{"key":"e_1_3_2_51_2","unstructured":"Imbruvica (ibrutinib) [package insert]. Sunnyvale CA: Pharmacyclics https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205552s007lbl.pdf (2016 accessed 9 March 2024)."},{"key":"e_1_3_2_52_2","unstructured":"Imbruvica (ibrutinib) [package insert]. Sunnyvale CA: Pharmacyclics . https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44 (2024 accessed 9 March 2024)."},{"key":"e_1_3_2_53_2","article-title":"Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US","volume":"29","author":"Yang X","unstructured":"Yang X, Zanardo E, Lejeune D, et al. Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US. Oncologist 2024 Mar 4; 29: e360\u2013e371.","journal-title":"Oncologist"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5091"},{"key":"e_1_3_2_55_2","article-title":"Trends in medicare spending on oral drugs for chronic lymphocytic leukemia from 2014 to 2020","volume":"6","author":"Cliff ERS","unstructured":"Cliff ERS, Kesselheim AS, Rome BN, et al. Trends in medicare spending on oral drugs for chronic lymphocytic leukemia from 2014 to 2020. JAMA Netw Open 2023 Apr 3; 6: e237467.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_2_56_2","unstructured":"Rind DM Agboola F Kumar VM et al. Unsupported price increase report: 2019 assessment. institute for clinical and economic review https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_UPI_Final_Report_and_Assessment_110619.pdf (2019 Nov 6 accessed 9 February 2024)."},{"key":"e_1_3_2_57_2","unstructured":"Rind DM Agboola F Chapman R et al. Unsupported price increase report: 2020 assessment. institute for clinical and economic review https:\/\/icer.org\/assessment\/unsupported-price-increase-2021\/ (2021 Jan 12 accessed 9 February 2024)."},{"key":"e_1_3_2_58_2","unstructured":"Rind DM Agboola F Nikitin D et al. Unsupported price increase report: unsupported price increases occurring in 2020. Institute for Clinical and Economic Review https:\/\/icer.org\/assessment\/unsupported-price-increase-2020\/ (2021 Dec 6 accessed 9 February 2024)."},{"key":"e_1_3_2_59_2","unstructured":"Rind DM Agboola F Campbell J et al. Unsupported price increase report: unsupported price increases occurring in 2021. Institute for Clinical and Economic Review https:\/\/icer.org\/assessment\/upi-2022\/ (2022 Dec 6 accessed 9 February 2024)."},{"key":"e_1_3_2_60_2","unstructured":"Rind DM Agboola F Nikitin D et al. Unsupported price increase report: unsupported price increases occurring in 2022. Institute for Clinical and Economic Review https:\/\/icer.org\/wp-content\/uploads\/2023\/12\/UPI_2023_Report_121123.pdf (2023 Dec 11 accessed 9 February 2024)."},{"key":"e_1_3_2_61_2","first-page":"14","article-title":"Estimating 2019 out-of-pocket cost of oral medications for metastatic renal cell carcinoma for medicare part D members","volume":"1","author":"Borrelli EP","unstructured":"Borrelli EP, McGladrigan CG. Estimating 2019 out-of-pocket cost of oral medications for metastatic renal cell carcinoma for medicare part D members. Oncolytics Today 2019 Fall; 1: 14\u201316.","journal-title":"Oncolytics Today"},{"key":"e_1_3_2_62_2","unstructured":"Kaiser Family Foundation. An overview of the medicare part d prescription drug benefit. Kaiser Family Foundation https:\/\/www.kff.org\/medicare\/fact-sheet\/an-overview-of-the-medicare-part-d-prescription-drug-benefit\/ (2023 Oct 17 accessed 21 February 2024)."},{"key":"e_1_3_2_63_2","unstructured":"Connor TH MacKenzie BA De Bord DG et al. NIOSH list of hazardous drugs in healthcare settings 2020. Centers for Disease Control and Prevention National Institute for Occupational Safety and Health https:\/\/www.cdc.gov\/niosh\/docket\/review\/docket233c\/pdfs\/DRAFT-NIOSH-Hazardous-Drugs-List-2020.pdf (2020 accessed 6 June 2024)."},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221135121"},{"key":"e_1_3_2_65_2","unstructured":"United States Department of Labor: Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. United States Department of Labor: Occupational Safety and Health Administration https:\/\/www.osha.gov\/hazardous-drugs\/controlling-occex (2024 accessed 6 June 2024)."},{"key":"e_1_3_2_66_2","unstructured":"Lisinopril [package insert]. Actavis Pharma Inc https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=43e2c8d1-3704-4323-bcaf-f582572b81f7 (2017 accessed 6 June 2024)."},{"key":"e_1_3_2_67_2","unstructured":"Enalapril [package insert]. Chartwell Rx LLC https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b1df1832-dce4-443f-87fc-e4177d069035 (2023 accessed 6 June 2024)."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093"},{"key":"e_1_3_2_70_2","article-title":"Fixed-Duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater AP","unstructured":"Kater AP, Owen C, Moreno CF, et al. Fixed-Duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022 Jul; 1: EVIDoa2200006.","journal-title":"NEJM Evid"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241306704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241306704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241306704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:55:37Z","timestamp":1779274537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241306704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552241306704"],"URL":"https:\/\/doi.org\/10.1177\/10781552241306704","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}